These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis: role of gadolinium?]. Kintossou R; D'Incan M; Chauveau D; Bens G; Franck F; Dauplat MM; Viraben R; Déchelotte P; Souteyrand P Ann Dermatol Venereol; 2007; 134(8-9):667-71. PubMed ID: 17925692 [TBL] [Abstract][Full Text] [Related]
10. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Morcos SK Br J Radiol; 2007 Feb; 80(950):73-6. PubMed ID: 17392401 [No Abstract] [Full Text] [Related]
11. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. Edward M; Quinn JA; Mukherjee S; Jensen MB; Jardine AG; Mark PB; Burden AD J Pathol; 2008 Apr; 214(5):584-93. PubMed ID: 18220317 [TBL] [Abstract][Full Text] [Related]
12. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456 [TBL] [Abstract][Full Text] [Related]
14. The evolution of osseous metaplasia in localized cutaneous nephrogenic systemic fibrosis: a case report. Wiedemeyer K; Kutzner H; Abraham JL; Thakral C; Carlson JA; Tran TA; Hausser I; Hartschuh W Am J Dermatopathol; 2009 Oct; 31(7):674-81. PubMed ID: 19633532 [TBL] [Abstract][Full Text] [Related]
15. Transmetallation and gadolinium: do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients? Panesar M; Boateng F; Patel SS; Masood SF; Mahajan P; Patel N; Murray B Hemodial Int; 2010 Jul; 14(3):289-94. PubMed ID: 20662951 [TBL] [Abstract][Full Text] [Related]
16. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? Thomsen HS; Morcos SK; Dawson P Clin Radiol; 2006 Nov; 61(11):905-6. PubMed ID: 17018301 [No Abstract] [Full Text] [Related]
17. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure. Grobner T; Prischl FC Semin Dial; 2008; 21(2):135-9. PubMed ID: 18226001 [TBL] [Abstract][Full Text] [Related]
18. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Richmond H; Zwerner J; Kim Y; Fiorentino D Arch Dermatol; 2007 Aug; 143(8):1025-30. PubMed ID: 17709661 [TBL] [Abstract][Full Text] [Related]
19. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Idée JM; Port M; Medina C; Lancelot E; Fayoux E; Ballet S; Corot C Toxicology; 2008 Jun; 248(2-3):77-88. PubMed ID: 18440117 [TBL] [Abstract][Full Text] [Related]
20. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor. Moreno-Romero JA; Segura S; Mascaró JM; Cowper SE; Julià M; Poch E; Botey A; Herrero C Br J Dermatol; 2007 Oct; 157(4):783-7. PubMed ID: 17627792 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]